Immune marker changes and risk of multiple myeloma : a nested case-control study using repeated prediagnostic blood samples
Biomarkers reliably predicting progression to multiple myeloma (MM) are lacking. Myeloma risk has been associated with low blood levels of monocyte chemotactic protein-3 (MCP-3), macrophage inflammatory protein-1 alpha (MIP-1 alpha), vascular endothelial growth factor (VEGF), fibroblast growth facto...
Published in: | Haematologica |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Umeå universitet, Onkologi
2019
|
Subjects: | |
Online Access: | http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-156420 https://doi.org/10.3324/haematol.2019.216895 |
id |
ftumeauniv:oai:DiVA.org:umu-156420 |
---|---|
record_format |
openpolar |
spelling |
ftumeauniv:oai:DiVA.org:umu-156420 2023-10-09T21:54:36+02:00 Immune marker changes and risk of multiple myeloma : a nested case-control study using repeated prediagnostic blood samples Späth, Florentin Wibom, Carl Krop, Esmeralda Izarra Santamaria, Antonio Johansson, Ann Sofie Bergdahl, Ingvar Hultdin, Johan Vermeulen, Roel Melin, Beatrice S. 2019 application/pdf http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-156420 https://doi.org/10.3324/haematol.2019.216895 eng eng Umeå universitet, Onkologi Umeå universitet, Enheten för biobanksforskning Umeå universitet, Klinisk kemi Utrecht University Haematologica, 0390-6078, 2019, 104:12, s. 2456-2464 orcid:0000-0002-0711-0830 orcid:0000-0003-1227-6859 http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-156420 doi:10.3324/haematol.2019.216895 PMID 30948485 ISI:000499687600030 Scopus 2-s2.0-85075958352 info:eu-repo/semantics/openAccess prospective longitudinal study multiple myeloma risk progression marker trajectories Clinical Medicine Klinisk medicin Article in journal info:eu-repo/semantics/article text 2019 ftumeauniv https://doi.org/10.3324/haematol.2019.216895 2023-09-22T13:52:05Z Biomarkers reliably predicting progression to multiple myeloma (MM) are lacking. Myeloma risk has been associated with low blood levels of monocyte chemotactic protein-3 (MCP-3), macrophage inflammatory protein-1 alpha (MIP-1 alpha), vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), fractalkine, and transforming growth factor-alpha (TGF-alpha). In this study, we aimed to replicate these findings and study the individual dynamics of each marker in a prospective longitudinal cohort, thereby examining their potential as markers of myeloma progression. For this purpose, we identified 65 myeloma cases and 65 matched cancer-free controls each with two donated blood samples within the Northern Sweden Health and Disease Study. The first and repeated samples from myeloma cases were donated at a median 13 and 4 years, respectively, before the myeloma was diagnosed. Known risk factors for progression were determined by protein-, and immunofixation electrophoresis, and free light chain assays. We observed lower levels of MCP-3, VEGF, FGF-2, and TGF-alpha in myeloma patients than in controls, consistent with previous data. We also observed that these markers decreased among future myeloma patients while remaining stable in controls. Decreasing trajectories were noted for TGF-alpha (P=2.5 x 10(-4)) indicating progression to MM. Investigating this, we found that low levels of TGF-alpha assessed at the time of the repeated sample were independently associated with risk of progression in a multivariable model (hazard ratio = 3.5; P=0.003). TGF-alpha can potentially improve early detection of MM. Originally included in thesis in manuscript form Article in Journal/Newspaper Northern Sweden Umeå University: Publications (DiVA) Haematologica 104 12 2456 2464 |
institution |
Open Polar |
collection |
Umeå University: Publications (DiVA) |
op_collection_id |
ftumeauniv |
language |
English |
topic |
prospective longitudinal study multiple myeloma risk progression marker trajectories Clinical Medicine Klinisk medicin |
spellingShingle |
prospective longitudinal study multiple myeloma risk progression marker trajectories Clinical Medicine Klinisk medicin Späth, Florentin Wibom, Carl Krop, Esmeralda Izarra Santamaria, Antonio Johansson, Ann Sofie Bergdahl, Ingvar Hultdin, Johan Vermeulen, Roel Melin, Beatrice S. Immune marker changes and risk of multiple myeloma : a nested case-control study using repeated prediagnostic blood samples |
topic_facet |
prospective longitudinal study multiple myeloma risk progression marker trajectories Clinical Medicine Klinisk medicin |
description |
Biomarkers reliably predicting progression to multiple myeloma (MM) are lacking. Myeloma risk has been associated with low blood levels of monocyte chemotactic protein-3 (MCP-3), macrophage inflammatory protein-1 alpha (MIP-1 alpha), vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), fractalkine, and transforming growth factor-alpha (TGF-alpha). In this study, we aimed to replicate these findings and study the individual dynamics of each marker in a prospective longitudinal cohort, thereby examining their potential as markers of myeloma progression. For this purpose, we identified 65 myeloma cases and 65 matched cancer-free controls each with two donated blood samples within the Northern Sweden Health and Disease Study. The first and repeated samples from myeloma cases were donated at a median 13 and 4 years, respectively, before the myeloma was diagnosed. Known risk factors for progression were determined by protein-, and immunofixation electrophoresis, and free light chain assays. We observed lower levels of MCP-3, VEGF, FGF-2, and TGF-alpha in myeloma patients than in controls, consistent with previous data. We also observed that these markers decreased among future myeloma patients while remaining stable in controls. Decreasing trajectories were noted for TGF-alpha (P=2.5 x 10(-4)) indicating progression to MM. Investigating this, we found that low levels of TGF-alpha assessed at the time of the repeated sample were independently associated with risk of progression in a multivariable model (hazard ratio = 3.5; P=0.003). TGF-alpha can potentially improve early detection of MM. Originally included in thesis in manuscript form |
format |
Article in Journal/Newspaper |
author |
Späth, Florentin Wibom, Carl Krop, Esmeralda Izarra Santamaria, Antonio Johansson, Ann Sofie Bergdahl, Ingvar Hultdin, Johan Vermeulen, Roel Melin, Beatrice S. |
author_facet |
Späth, Florentin Wibom, Carl Krop, Esmeralda Izarra Santamaria, Antonio Johansson, Ann Sofie Bergdahl, Ingvar Hultdin, Johan Vermeulen, Roel Melin, Beatrice S. |
author_sort |
Späth, Florentin |
title |
Immune marker changes and risk of multiple myeloma : a nested case-control study using repeated prediagnostic blood samples |
title_short |
Immune marker changes and risk of multiple myeloma : a nested case-control study using repeated prediagnostic blood samples |
title_full |
Immune marker changes and risk of multiple myeloma : a nested case-control study using repeated prediagnostic blood samples |
title_fullStr |
Immune marker changes and risk of multiple myeloma : a nested case-control study using repeated prediagnostic blood samples |
title_full_unstemmed |
Immune marker changes and risk of multiple myeloma : a nested case-control study using repeated prediagnostic blood samples |
title_sort |
immune marker changes and risk of multiple myeloma : a nested case-control study using repeated prediagnostic blood samples |
publisher |
Umeå universitet, Onkologi |
publishDate |
2019 |
url |
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-156420 https://doi.org/10.3324/haematol.2019.216895 |
genre |
Northern Sweden |
genre_facet |
Northern Sweden |
op_relation |
Haematologica, 0390-6078, 2019, 104:12, s. 2456-2464 orcid:0000-0002-0711-0830 orcid:0000-0003-1227-6859 http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-156420 doi:10.3324/haematol.2019.216895 PMID 30948485 ISI:000499687600030 Scopus 2-s2.0-85075958352 |
op_rights |
info:eu-repo/semantics/openAccess |
op_doi |
https://doi.org/10.3324/haematol.2019.216895 |
container_title |
Haematologica |
container_volume |
104 |
container_issue |
12 |
container_start_page |
2456 |
op_container_end_page |
2464 |
_version_ |
1779318230552150016 |